Morgan Stanley on BioMarin Pharmaceutical Inc. (BMRN): 'we think the settlement recognizes the value of BioMarin’s pioneering CNP innovation'
August 31, 2026 11:01 AM
Morgan Stanley analyst Sean Laaman reiterated an Overweight rating and $124.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
